Genotype-Guided Use of P2Y12 Inhibitors: A Review of Current State of the Art

Genotype-Guided Use of P2Y12 Inhibitors: A Review of Current State of the Art

The pharmacodynamics of the purinergic receptor type Y, subtype 12 (P2Y12) inhibitors has evolved. Our understanding of the metabolism of P2Y12 inhibitors has revealed polymorphisms that impact drug metabolism and antiplatelet efficacy, leading to genetic testing guided therapy. In addition, assays...

Full description

Bibliographic Details
Main Authors: Abdullah Al-abcha, Yasser Radwan, Danielle Blais, Ernest L. Mazzaferri, Konstantinos Dean Boudoulas, Essa M. Essa, Richard J. Gumina
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-03-01
Series:Frontiers in Cardiovascular Medicine
Subjects:
genotype
P2Y12
guided therapy
platelet
function
Online Access:https://www.frontiersin.org/articles/10.3389/fcvm.2022.850028/full

Internet

https://www.frontiersin.org/articles/10.3389/fcvm.2022.850028/full

Similar Items